### POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al. Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET

1	CAAACTTGGT	GGCAACTTGC	CTCCCGGTGC	GGGCGTCTCT	CCCCCACCGT
51	CTCAA C <u>ATG</u> C	TTAGGGGTCC	GGGCCCGGG	CTGCTGCTGC	TGGCCGTCCA
101	GTGCCTGGGG	ACAGCGGTGC	CCTCCACGGG	AGCCTCGAAG	AGCAAGAGGC
151	AGGCTCAGCA	AATGGTTCAG	CCCCAGTCCC	CGGTGGCTGT	CAGTCAAAGC
201	AAGCCCGGTT	GTTATGACAA	TGGAAAACAC	TATCAGATAA	ATCAACAGTG
251	GGAGCGGACC	TACCTAGGCA	ATGCGTTGGT	TTGTACTTGT	TATGGAGGAA
301	GCCGAGGTTT	TAACTGCGAG	AGTAAACCTG	AAGCTGAAGA	GACTTGCTTT
351	GACAAGTACA	CTGGGAACAC	TTACCGAGTG	GGTGACACTT	ATGAGCGTCC
401	TAAAGACTCC	ATGATCTGGG	ACTGTACCTG	CATCGGGGCT	GGGCGAGGGA
451	GAATAAGCTG	TACCATCGCA	AACCGCTGCC	ATGAAGGGGG	TCAGTCCTAC
501	AAGATTGGTG	ACACCTGGAG	GAGACCACAT	GAGACTGGTG	GTTACATGTT
551	AGAGTGTGTG	TGTCTTGGTA	ATGGAAAAGG	AGAATGGACC	TGCAAGCCCA
601	TAGCTGAGAA	GTGTTTTGAT	CATGCTGCTG	GGACTTCCTA	TGTGGTCGGA
651	GAAACGTGGG	AGAAGCCCTA	CCAAGGCTGG	ATGATGGTAG	ATTGTACTTG
701	CCTGGGAGAA	GGCAGCGGAC	GCATCACTTG	CACTTCTAGA	AATAGATGCA
751	ACGATCAGGA	CACAAGGACA	TCCTATAGAA	TTGGAGACAC	CTGGAGCAAG
801	AAGGATAATC	GAGGAAACCT	GCTCCAGTGC	ATCTGCACAG	GCAACGGCCG
851	AGGAGAGTGG	AAGTGTGAGA	GGCACACCTC	TGTGCAGACC	ACATCGAGCG
901	GATCTGGCCC	CTTCACCGAT	GTTCGTGCAG	CTGTTTACCA	ACCGCAGCCT
951	CACCCCCAGC	CTCCTCCCTA	TGGCCACTGT	GTCACAGACA	GTGGTGTGGT
1001	CTACTCTGTG	GGGATGCAGT	GGCTGAAGAC	ACAAGGAAAT	AAGCAAATGC
1051	TTTGCACGTG	CCTGGGCAAC	GGAGTCAGCT	GCCAAGAGAC	AGCTGTAACC

# Fig. 1 (part 1)

#### POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al. Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET

CAGACTTACG GTGGCAACTC AAATGGAGAG CCATGTGTCT TACCATTCAC 1101 CTACAACGAC AGGACGGACA GCACAACTTC GAATTATGAG CAGGACCAGA 1151 AATACTCTTT CTGCACAGAC CACACTGTTT TGGTTCAGAC TCGAGGAGGA 1201 AATTCCAATG GTGCCTTGTG CCACTTCCCC TTCCTATACA ACAACCACAA 1251 TTACACTGAT TGCACTTCTG AGGGCAGAAG AGACAACATG AAGTGGTGTG 1301 GGACCACACA GAACTATGAT GCCGACCAGA AGTTTGGGTT CTGCCCCATG 1351 GCTGCCCACG AGGAAATCTG CACAACCAAT GAAGGGGTCA TGTACCGCAT 1401 TGGAGATCAG TGGGATAAGC AGCATGACAT GGGTCACATG ATGAGGTGCA 1451 CGTGTGTTGG GAATGGTCGT GGGGAATGGA CATGCATTGC CTACTCGCAG 1501 CTTCGAGATC AGTGCATTGT TGATGACATC ACTTACAATG TGAACGACAC 1551 ATTCCACAAG CGTCATGAAG AGGGGCACAT GCTGAACTGT ACATGCTTCG 1601 GTCAGGGTCG GGGCAGGTGG AAGTGTGATC CCGTCGACCA ATGCCAGGAT 1651 TCAGAGACTG GGACGTTTTA TCAAATTGGA GATTCATGGG AGAAGTATGT 1701 GCATGGTGTC AGATACCAGT GCTACTGCTA TGGCCGTGGC ATTGGGGAGT 1751 GGCATTGCCA ACCTTTACAG ACCTATCCAA GCTCAAGTGG TCCTGTCGAA 1801 GTATTTATCA CTGAGACTCC GAGTCAGCCC AACTCCCACC CCATCCAGTG 1851 GAATGCACCA CAGCCATCTC ACATTTCCAA GTACATTCTC AGGTGGAGAC 1901 CTGTGAGTAT CCCACCCAGA AACCTTGGAT ACTGAGTCTC CTAATCTTAT 1951 CAATTCTGAT GGTTTCTTTT TTTCCCAGCT TTTGAGCCAA CAACTCTGAT 2001 TAACTATTCC TATAGCATTT ACTATATTTG TTTAGTGAAC AAACAATATG 2051 TGGTCAATTA AATTGACTTG TAGACTGAAA AAAAAAAAA AAAAAAA 2101

## Fig. 1 (part 2)

## POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al.

Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET

			1.7			
	10	20	30	40	50	6.0
pMSF-1α	NLVATCLPVRASL	PHRLNMLRGP	GPGLLLLAVO	CLGTAVPST	GASKSKRODOC	O O O O O O O O O O O O O O O O O O O
		7111111111	11111111111		5	1111111
fibronectin	NLVATCLPVRASI	PHRLNMLRGP	GPGLLLLAV	CLGTAVPST	GASKSKROAOC	MVOPOSP
		•	10	20	30	40
n Man a	70	80	90	100	110	120
p MSF-1α	VAVSQSKPGCYDN	GKHYQINQQW	ertylgnalv	CTCYGGSRG	FNCESKPEAEE	TCFDKYT
fibropection	WAY GOOD COVERN		<u>                                     </u>		111111111	1111111
rapionectin	VAVSQSKPGCYDN 50	€0 GKHIĞIMĞĞM				TCFDKYT
	50	60	70	80	90	100
	130	140	150	160	170	
p MSF-1α	GNTYRVGDTYERP			160	170	180
<u>r</u>		IIIIIIIIII			3QSYKIGDTWR	RPHETGG
fibronectin	GNTYRVGDTYERP	KDSMIWDCTC	TGAGRGRISC			
*	110	120	130	140	150	RPHETGG 160
					130	160
	190	200	210	220	230	240
pMSF-1α	YMLECVCLGNGKG	EWTCKPIAEK	CFDHAAGTSY	VVGETWEKP:		T.GEGGGD
			111111111			111111
fibronectin	YMLECVCLGNGKG	EWTCKPIAEK	CFDHAAGTSY	VVGETWEKP	YQGWMMVDCTC	LGEGSGR
•	170	180	190	200	210	220
				•		
16077 4	250	260	270	280	290	300
pMSF-1α	ITCTSRNRCNDQD	TRTSYRIGDT	WSKKDNRGNI	LOCICTONG	RGEWKCERHTS	VQTTSSG
fibropactio	TTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT					
rrpronecciii	ITCTSRNRCNDOD	TRISTRIGDT 240	WSKKDNRGNI			VQTTSSG
	250	240	250	260	270	280
	310	320	330	340	350	2.60
pMSF-1α	SGPFTDVRAAVYQ	<del>-</del>			350	360
<b>E</b>				/12/GMQWLK	TOGNKOMPCJO	CLGNGVSC
fibronectin	SGPFTDVRAAVYQ	POPHPOPPPY	GHCVTDSGV\	//SVGMOWLE	IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	
	290	300	310	320	330	340
					330	340
	370	380			390 4	100
PMSF-1α	QETAVTQTYGGNS	NGEPCVLPFT	YNDRT		-DSTTSNYEQI	
		1111111111	11:11		111111111	111111
fibronectin	QETAVTQTYGGNS	NGEPCVLPFT	YNGRTFYSC	TTEGRQDGHL	WCSTTSNYEO	OKYSECT
	350	360	370	380	390	400
n 1/07 4				440	450 4	160
PMSF-1α	DHTVLVQTRGGNS	NGALCHFPFL	YNNHNYTDC	<b>ISEGRRDNMK</b>	WCGTTQNYDAI	OOKFGFCP
fibronostis	_ 1	11111111	11111111	3	1111111111	
ribionectin	- DHIVIOUGINS	INGALCHEDET.	ッヘススススススススススススススススススススススススススススススススススススス	アクサイロ ひりかれれい	Maammaa	
	DHTVLVQTQGGNS	420	TIMMINITIDO.	TOPOKKDIMIK	MCGTTQNYDAI	DQKFGFCP
	410	420	430	440	WCGTTQNYDAI 450	QKFGFCP 460

Fig. 2 (part 1)

## POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al.

Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET




Fig. 2 (part 2)

# POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al. Appl. No.: 09/581,651 Atty Docket: ERP01.003APC

[SEQ ID NO; 13]	5' untranslated region
[SEQ ID NO:14]	Signal
[SEQ ID NO: 15]	NH2-terminal segment
[SEQ ID NO: 16]	
[SEQ ID NO: 38]	I Fibrin
[SEQ ID NO: 39]	I Heparin
[SEQ ID NO: 40]	I S. aureus
[SEQ ID NO:17]	H
[SEQ ID NO:18]	Connecting strand
[SEQ ID NO: 19]	H
[SEQ ID NO: 20]	II
[SEQ ID NO: 28]	II Gelatin
ID NO:	H
ID NO:	н н
[SEQ ID NO. 24]	III
[SEQ ID NO: 25]	Unique Sequence

POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al.

Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET




Fig. 4

POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF Schor et al. Appl. No.: 09/581,651 Atty Docket: ERP01.003APC REPLACEMENT SHEET

